Evaluation of the cholinesterase activity of a potential therapeutic cocaine esterase for cocaine overdose.


Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 09 2019
Historique:
received: 28 11 2018
revised: 06 04 2019
accepted: 30 04 2019
pubmed: 29 7 2019
medline: 24 3 2020
entrez: 29 7 2019
Statut: ppublish

Résumé

Cocaine is a commonly abused drug and there is no approved medication specifically to treat its addiction or overdose. Bacterial cocaine esterase (CocE)-derived RBP-8000 is currently under clinical development for cocaine overdose treatment. It is proven to be effective for human use to accelerate cocaine metabolism into physiologically inactive products. Besides cocaine, RBP-8000 may hydrolyze the neurotransmitter acetylcholine (ACh), however, no study has reported its cholinesterase activity. The present study aims to examine RBP-8000's cholinesterase activity and substrate selectivity to address the potential concern that this enzyme therapy might produce cholinergic side-effects. Both computational modeling and experimental kinetic analysis were carried out to characterize the potential cholinesterase activity of RBP-8000. Substrates interacting with RBP-8000 were modeled for their enzyme-substrate binding complexes. In vitro enzymatic kinetic parameters were measured using Ellman's colorimetric assay and analyzed by Michaelis-Menten kinetics. It is the first demonstration that RBP-8000 catalyzes the hydrolysis of acetylthiocholine (ATC). However, its catalytic efficiency (k Given the fact that clinically relevant dose of RBP-8000 displays insignificant cholinesterase activity relative to endogenous cholinesterases in human, administration of RBP-8000 is unlikely to produce any significant cholinergic side-effects. This study provides supplemental evidences in support of further development of RBP-8000 towards a clinically used pharmacotherapy for cocaine overdose.

Sections du résumé

BACKGROUND
Cocaine is a commonly abused drug and there is no approved medication specifically to treat its addiction or overdose. Bacterial cocaine esterase (CocE)-derived RBP-8000 is currently under clinical development for cocaine overdose treatment. It is proven to be effective for human use to accelerate cocaine metabolism into physiologically inactive products. Besides cocaine, RBP-8000 may hydrolyze the neurotransmitter acetylcholine (ACh), however, no study has reported its cholinesterase activity. The present study aims to examine RBP-8000's cholinesterase activity and substrate selectivity to address the potential concern that this enzyme therapy might produce cholinergic side-effects.
METHODS
Both computational modeling and experimental kinetic analysis were carried out to characterize the potential cholinesterase activity of RBP-8000. Substrates interacting with RBP-8000 were modeled for their enzyme-substrate binding complexes. In vitro enzymatic kinetic parameters were measured using Ellman's colorimetric assay and analyzed by Michaelis-Menten kinetics.
RESULTS
It is the first demonstration that RBP-8000 catalyzes the hydrolysis of acetylthiocholine (ATC). However, its catalytic efficiency (k
CONCLUSION
Given the fact that clinically relevant dose of RBP-8000 displays insignificant cholinesterase activity relative to endogenous cholinesterases in human, administration of RBP-8000 is unlikely to produce any significant cholinergic side-effects. This study provides supplemental evidences in support of further development of RBP-8000 towards a clinically used pharmacotherapy for cocaine overdose.

Identifiants

pubmed: 31352306
pii: S0376-8716(19)30222-4
doi: 10.1016/j.drugalcdep.2019.04.034
pii:
doi:

Substances chimiques

Bacterial Proteins 0
Acetylthiocholine 4468-05-7
Carboxylic Ester Hydrolases EC 3.1.1.-
cocaine esterase EC 3.1.1.-
Cholinesterases EC 3.1.1.8
RBP-8000 ENI788PTL9
Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

168-171

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Shurong Hou (S)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China.

Yun Zhang (Y)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China.

Yao Zhu (Y)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China.

Chao Zhang (C)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China.

Yichao Kong (Y)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China.

Xiaoling Chen (X)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China.

Rong Chen (R)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China.

Xiaopu Yin (X)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China.

Tian Xie (T)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China. Electronic address: xbs@dljg.sina.net.

Xiabin Chen (X)

Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University. 2318 Yuhangtang Rd, Hangzhou, Zhejiang 311121, China. Electronic address: xch226@hznu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH